Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00267371 · ClinicalTrials.gov registry record · Phase 3
ESCAPE Migraine Trial
A Phase 3 study, sponsored by Abbott Medical Devices.
- Terminated
- Registry status
- Phase 3
- Development phase
- 168
- Enrollment target
NCT00267371 is a Phase 3 study that was terminated before completion, run by Abbott Medical Devices. The registered enrollment target is 168 participants.
The verdict
NCT00267371, a Phase 3 study, was terminated before completion, sponsored by Abbott Medical Devices.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 168 participants
- Enrollment target
Study Summary
The purpose of this two arm controlled double-blind study is to determine the safety and effectiveness of PFO closure (closing a hole in the wall of the heart) in reducing the frequency of migraine headaches, in patients who experience migraine headaches and have a PFO, compared to medical therapy alone.
Interventions
- DEVICE PFO Closure with Premere investigational device.
- DRUG Medical management/current medications per standard of care by personal physician.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 168 participants |
| Start Date | 2005-11 |
| Est. Completion | 2012-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00267371
The ClinicalTrials.gov registry entry for NCT00267371 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 168 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott Medical Devices, which has 261 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which PFO Closure with Premere investigational device. is the first listed.
NCT00267371 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00267371 about?
NCT00267371 is a clinical study titled "ESCAPE Migraine Trial". The purpose of this two arm controlled double-blind study is to determine the safety and effectiveness of PFO closure (closing a hole in the wall of the heart) in reducing the frequency of migraine headaches, in patients who experience migraine headaches and have a PFO, compared to medical therapy a...
What is the current status of trial NCT00267371?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 168 participants. The study started on 2005-11. Estimated completion is 2012-03.
What interventions are being tested in trial NCT00267371?
The interventions under investigation include: PFO Closure with Premere investigational device. (DEVICE), Medical management/current medications per standard of care by personal physician. (DRUG).
Who is sponsoring clinical trial NCT00267371?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.